Page last updated: 2024-11-05

thalidomide and Sarcoma 180

thalidomide has been researched along with Sarcoma 180 in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Sarcoma 180: An experimental sarcoma of mice.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, D1
Fu, J1
Shi, Y1
Peng, D1
Yuan, L1
He, B1
Dai, W1
Zhang, H1
Wang, X1
Tian, J1
Zhang, Q1

Other Studies

1 other study available for thalidomide and Sarcoma 180

ArticleYear
The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model.
    Journal of controlled release : official journal of the Controlled Release Society, 2016, 09-28, Volume: 238

    Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Apoptosis; Capillary Permeability; Do

2016